RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+25.77%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$4.05B
AUM Growth
+$4.05B
(+8.5%)
Cap. Flow
-$190M
Cap. Flow
% of AUM
-4.69%
Top 10 Holdings %
Top 10 Hldgs %
37.5%
Holding
124
New
3
Increased
35
Reduced
29
Closed
20
Top Buys
| 1 |
Eli Lilly
LLY
|
$40.5M |
| 2 |
Celldex Therapeutics
CLDX
|
$18.6M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$18.1M |
| 4 |
Immunovant
IMVT
|
$14.3M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$13.3M |
Top Sells
Sector Composition
| 1 | Healthcare | 97.34% |
| 2 | Consumer Staples | 1.42% |
| 3 | Industrials | 1.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
1
DELISTED
Blueprint Medicines
BPMC
| $266M | 6.54% | 2,881,567 +196,273 | +7% | +$18.1M |
|
2
Immunocore
IMCR
$1.62B
| $182M | 4.48% | 2,661,507 -282,203 | -10% | -$19.3M |
|
|
KRTX
3
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $163M | 4.01% | 515,024 +9,591 | +2% | +$3.04M |
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $158M | 3.88% | 1,196,000 -40,000 | -3% | -$5.27M |
|
5
Humana
HUM
$36.5B
| $142M | 3.49% | 310,000 -126,500 | -29% | -$57.9M |
|
6
Penumbra
PEN
$10.6B
| $135M | 3.33% | 537,500 +33,750 | +7% | +$8.49M |
|
7
Evolent Health
EVH
$1.12B
| $131M | 3.22% | 3,960,000 +95,000 | +2% | +$3.14M |
|
8
UnitedHealth
UNH
$281B
| $121M | 2.98% | 230,000 | – | – |
|
|
CERE
9
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $113M | 2.79% | 2,674,245 +145,129 | +6% | +$6.15M |
|
10
Agilon Health
AGL
$530M
| $108M | 2.67% | 8,630,000 +337,500 | +4% | +$4.24M |
|
11
Intuitive Surgical
ISRG
$170B
| $101M | 2.48% | 298,500 | – | – |
|
12
Idexx Laboratories
IDXX
$51.8B
| $99.5M | 2.45% | 179,250 -15,250 | -8% | -$8.46M |
|
13
Insulet
PODD
$23.9B
| $93.7M | 2.31% | 431,750 +51,750 | +14% | +$11.2M |
|
14
argenx
ARGX
$43.6B
| $87.2M | 2.15% | 229,250 -29,750 | -11% | -$11.3M |
|
|
15
Ultragenyx Pharmaceutical
RARE
$2.89B
| $83.9M | 2.06% | 1,754,038 +277,597 | +19% | +$13.3M |
|
16
Acadia Healthcare
ACHC
$2.12B
| $83.5M | 2.05% | 1,073,500 +165,500 | +18% | +$12.9M |
|
17
Exact Sciences
EXAS
$8.98B
| $75.4M | 1.86% | 1,019,500 +1,250 | +0.1% | +$92.5K |
|
18
DexCom
DXCM
$29.5B
| $74M | 1.82% | 596,000 +12,000 | +2% | +$1.49M |
|
19
Boston Scientific
BSX
$156B
| $71.3M | 1.75% | 1,232,500 +72,500 | +6% | +$4.19M |
|
20
Rhythm Pharmaceuticals
RYTM
$6.85B
| $70M | 1.72% | 1,522,893 -74,230 | -5% | -$3.41M |
|
21
Align Technology
ALGN
$10.3B
| $60.3M | 1.48% | 220,000 +3,000 | +1% | +$822K |
|
22
Xenon Pharmaceuticals
XENE
$2.98B
| $57.8M | 1.42% | 1,255,577 +77,575 | +7% | +$3.57M |
|
23
Freshpet
FRPT
$2.72B
| $57.5M | 1.42% | 662,500 | – | – |
|
24
Mirum Pharmaceuticals
MIRM
$3.71B
| $54.7M | 1.35% | 1,851,464 +30,731 | +2% | +$907K |
|
25
Phreesia
PHR
$1.88B
| $51.1M | 1.26% | 2,206,700 +430,309 | +24% | +$9.96M |
|